Pathophysiology
PKD1 (85%) or PKD2 (15%) mutations disrupt polycystin-1/2 in primary cilia; cysts enlarge, compress parenchyma, and reduce GFR.
Sources: KDIGO ADPKD 2024; TEMPO 3:4 Tolvaptan (NEJM 2012;367:2407)
Presentation
Hypertension in young adults, flank pain, gross haematuria, nephrolithiasis, palpable kidneys, intracranial berry aneurysms, hepatic cysts, mitral valve prolapse.
Diagnosis
Ultrasound criteria (Pei-Ravine) age-adjusted; genetic testing for atypical presentation. Screen for intracranial aneurysm if family history.
Management
BP control (<110/75 in young rapid progressors), high fluid intake, low sodium, avoid nephrotoxins. Tolvaptan (V2 antagonist) slows GFR decline in rapidly progressing PKD1.




